This paper examines the end-to-end bioprocess development lifecycle for a therapeutic monoclonal antibody (mAb), from molecule selection through commercial manufacturing and regulatory considerations. It integrates upstream cell line development, bioreactor process design, downstream purification, analytical characterization, formulation, scale-up, process validation, quality-by-design (QbD), risk assessment, and techno-economic analysis. Emphasis is placed on decision points that balance product quality, manufacturability, cost, and regulatory compliance, illustrated with data-driven examples and recommended best practices.
For mAb-X, the challenge was . In a small flask, oxygen diffuses easily. In a massive stainless steel tank, the cells in the center can starve for oxygen if mixing isn't perfect. A Mab A Case Study In Bioprocess Development
The TPP required 100 mg/mL in a liquid formulation. At this concentration, A Mab exhibited: For mAb-X, the challenge was
The polishing CEX step requires a 45 cm diameter column (Vantage VL). Packing at scale reveals a consistent "tilt" in the bed height. After four failed packs, the team switches to dynamic axial compression and reduces the slurry concentration from 50% to 35%, achieving a HETP (Height Equivalent to a Theoretical Plate) of <0.05. The TPP required 100 mg/mL in a liquid formulation
The is a landmark document in biopharmaceutical development, created by the CMC Biotech Working Group (a collaboration of major companies including Pfizer, Amgen, and GSK) to illustrate how Quality by Design (QbD) principles can be applied to monoclonal antibodies. 1. Core Purpose and Framework
: Determining Critical Quality Attributes (CQAs) —such as glycosylation, aggregation, and host cell protein (HCP) levels—that must be controlled to ensure drug performance.